Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $4.50

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $4.50.

Several brokerages recently commented on SGMO. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Tuesday. Royal Bank Of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Barclays decreased their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Finally, Wall Street Zen cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 30th.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 21,793 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Sangamo Therapeutics during the 4th quarter worth $353,000. Geode Capital Management LLC grew its holdings in Sangamo Therapeutics by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company’s stock worth $2,257,000 after acquiring an additional 73,540 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Sangamo Therapeutics by 222.1% during the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after acquiring an additional 698,296 shares during the period. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $0.56 on Tuesday. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The firm has a market cap of $129.95 million, a price-to-earnings ratio of -1.43 and a beta of 1.19. The stock’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.99.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. The firm had revenue of $6.44 million during the quarter, compared to the consensus estimate of $7.90 million. As a group, research analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.